ECSP10010540A -
USE OF DRONEDARONA FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR USE IN THE PREVENTION OF CARDIOVASCULAR HOSPITALIZATION OR MORTALITY
- Google Patents
USE OF DRONEDARONA FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR USE IN THE PREVENTION OF CARDIOVASCULAR HOSPITALIZATION OR MORTALITY
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0802127Aexternal-prioritypatent/FR2930148A1/en
Application filed by Sanofi AventisfiledCriticalSanofi Aventis
Publication of ECSP10010540ApublicationCriticalpatent/ECSP10010540A/en
Acyclic And Carbocyclic Compounds In Medicinal Compositions
(AREA)
Abstract
Uso de dronedarona o sales farmaceuticamente aceptables de la misma, para la preparacion de un medicamento para uso en la prevencion de la hospitalizacion cardiovascular o de la mortalidad.Use of dronedarone or pharmaceutically acceptable salts thereof, for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or mortality.
ECSP100105402008-04-172010-10-11
USE OF DRONEDARONA FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR USE IN THE PREVENTION OF CARDIOVASCULAR HOSPITALIZATION OR MORTALITY
ECSP10010540A
(en)
Use of dronedarone to prepare medicament to prevent mortality and/or cardiovascular hospitalizations in patients having e.g. history of atrial fibrillation/atrial flutter, cerebrovascular accident and non-rheumatic valvular heart disease
Use of a pharmaceutical composition comprising treprostinil for the preparation of a medicament for the treatment or prevention of a condition associated with cystic fibrosis.
USE OF DRONEDARONE OR A PHARMACEUTICALLY ACCEPTABLE SALT OF THIS, FOR THE PREPARATION OF A MEDICINAL PRODUCT TO REGULATE THE LEVEL OF POTASSIUM IN THE BLOOD
USE OF DRONEDARONE FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR USE IN THE PREVENTION OF CARDIOVASCULAR HOSPITALIZATION OR MORTALITY IN PA-HUNDREDS WHO HAVE A FIRST RECURRENCE OF HEADPHONES OR ALE-TEO HEADPHONES
USE OF DRONEDARONE FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE PREVENTION OF CARDIOVASCULAR HOSPITALIZATION OR OF MORTALITY IN PATIENTS WITH ISOLATED HEADPHONES FIBRILATION
USE OF DRONEDARONE FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE PREVENTION OF CARDIOVASCULAR HOSPITALIZATIONS OR DEATH OR CARDIOVASCULAR EVENTS IN PATIENTS WITH PERMANENT FIBRILATION